

## Special Issue

# An Update on CFTR Drug Discovery: Opportunities and Challenges

### Message from the Guest Editors

Cystic fibrosis transmembrane conductance regulator (CFTR) rescuing drugs have already transformed cystic fibrosis from a fatal disease to a treatable chronic condition. However, a new generation of drugs able to bind CFTR or other CF protein targets are needed.

These drugs are expected to act with high specificity and potency, thus exerting stronger therapeutic benefits and fewer side effects in comparison with drugs that are already marketed. This Special Issue will focus on *experimental* and *computational* studies in the research area of CF therapy. It will include identification and characterization studies of new chemical scaffolds and protein targets, evaluation of their molecular mechanism of action by means of several available tools, such as bioinformatics, biosensors, omics, and cellular tests.

---

### Guest Editors

Prof. Dr. Paola Fossa

Department of Pharmacy, Università degli Studi di Genova, Genoa, Italy

Dr. Pasqualina D'Ursi

Institute of Biomedical Technologies-CNR, Segrate, Italy

---

### Deadline for manuscript submissions

closed (28 February 2022)



## Biomolecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.2  
Indexed in PubMed



[mdpi.com/si/54166](https://mdpi.com/si/54166)

*Biomolecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomolecules@mdpi.com](mailto:biomolecules@mdpi.com)

[mdpi.com/journal/  
biomolecules](https://mdpi.com/journal/biomolecules)





# Biomolecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.2  
Indexed in PubMed



[mdpi.com/journal/  
biomolecules](https://mdpi.com/journal/biomolecules)



## About the Journal

### Message from the Editorial Board

*Biomolecules* is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

---

### Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

---

### Author Benefits

#### Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)